Importantly, phenotypic and clinical differences were noted by the mutated gene: DCIS was diagnosed at a younger age (not statistically significant), with a higher rate of intermediate-to-high-grade DCIS and ER negativity in BRCA1 PSV carriers compared with BRCA2 PSV carriers. This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.